<DOC>
	<DOC>NCT00837655</DOC>
	<brief_summary>The purpose of this study is to perform a randomized, controlled clinical trial to investigate if the phosphate binder sevelamer can improve insulin resistance and glucose handling in patients receiving maintenance hemodialysis.</brief_summary>
	<brief_title>Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Male or female patients 1880 years of age with chronic renal failure treated with maintenance HD for &gt;3 months. Diabetes mellitus Treatment with sevelamer within 3 months prior to enrollment Acute, clinically significant inflammation within 1 month prior to enrollment Pregnancy or breastfeeding Clinically significant obstipation or bowel obstruction Discontinuation of previous sevelamer treatment because of side effects Expected time in HD &lt; 1 year Unwillingness to undergo the investigations and followup required in the the protocol Patients who have received any investigational drug within 1 month prior to enrolment Participation in another study, which may interfere with the present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>phosphate binder</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>glucose intolerance</keyword>
	<keyword>sevelamer</keyword>
</DOC>